This clinical trial is focused on studying a condition known as Staphylococcus aureus bacteremia, which is a type of bacterial infection in the blood. The treatment being investigated is an antibiotic called cloxacillin. The purpose of the study is to determine if a measure of kidney function, known as the estimated glomerular filtration rate (eGFR), can help predict which patients might need adjustments in their cloxacillin dosage. This is done through a process called therapeutic drug monitoring (TDM), which involves checking the levels of the drug in the blood to ensure they are within a safe and effective range.

Participants in the study will receive cloxacillin through an intravenous route, meaning it will be administered directly into a vein. The study will monitor patients over a period of time to see how well the drug works and to check for any potential side effects. The researchers will pay special attention to how the drug levels relate to kidney function and whether patients reach the desired drug concentration in their blood. This will help in understanding if the standard dosing needs to be adjusted based on individual kidney function.

Throughout the study, various health markers will be observed, including any signs of kidney damage or changes in mental status, such as confusion or tremors. The study will also consider factors like age, weight, and other health conditions that might affect the treatment. By gathering this information, the study aims to improve the way cloxacillin is used to treat Staphylococcus aureus bacteremia, ensuring it is both safe and effective for patients with different levels of kidney function.